Publications
1. Graham, F.L., van der Eb., A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52, 456-467, 1973.
2. Graham, F.L., van der Eb, A.J. Transformation of rat cells by DNA of human adenovirus 5. Virology 54, 536-539, 1973
3. Graham, F.L., Veldhuisen, G., and Wilkie, N.M. Infectious Herpesvirus DNA. Nature New Biology 245, 265-266, 1973
6. Bacchetti, S., and Graham, F.L. Transfer of the gene for thymidine kinase to thymidine kinase-deficient human cells by purified herpes simplex viral DNA. Proc. Natl. Acad. Sci. U.S.A. 74, 1509-1594, 1977
4. Graham, F.L., van der Eb, A.J., and Heijneker, J.L. Size and location of the transforming region in human adenovirus type 5 DNA. Nature 251, 687-691, 1974
7. Graham, F.L. Biological activity of tumor virus DNA. Advances in Cancer Research, 25, pp. 1-51, 1977
8. Mak, S., Mak, I., Smiley, J.R., and Graham, F.L. Tumorigenicity and viral gene expression in rat cells transformed by Ad 12 virions or by the Eco RI C fragment of Ad 12 DNA Virology 98, 456-460, 1979
9. Bacchetti, S., and Graham, F.L.. Characterization of human TK cell lines transformed to a TK phenotype by herpes simplex virus type 2 DNA. J. Gen. Virol. 42, 149- 157, 1979
10. van der Eb, A.J., and Graham, F.L. Assay of transforming activity of tumor virus DNA. Methods in Enzymology: Nucleic Acids and Protein Synthesis. Vol. 65 (eds. L. Grossman and K. Moldave). Academic Press, N.Y., 1980.
11. Graham, F.L., Bacchetti, S., McKinnon, R., Stanners, C.P., Cordell, B.,and Goodman, H.M. Transformation of mammalian cells with DNA using the calcium technique Introduction of Macromolecules into Viable Mammalian Cells. Progress in Clinical and Biological Research (eds., B. Baserga, C. Croce, and G. Rovera). Alan Liss N.Y., 3-24, 1980.
5. van der Eb, A.J., Mulder, C., Graham, F.L., and Houweling, A. Transformation with specific fragments of adenovirus DNAs. I: Isolation of specific fragments with transforming activity of adenovirus 2 and 5 DNA. Gene 2, 115-132, 1977
15. Graham, F.L., Smiley, J., Russell, W.C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-72, 1977
16. Graham. F.L. Growth of 293 cells in suspension culture. J. Gen. Virol. 68: 937-940, 1987
20. Chen, L., Anton, M. and Graham, F. L. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat. Cell and Molec. Genet. 22: 477-488, 1996
21. Louis, N., Evelegh, C. and Graham, F. L. Cloning and sequencing of the cellular/viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology, 233:423-429, 1997
12. Graham, F.L., and Bacchetti, S. DNA mediated gene transfer using the calcium technique Techniques in the Life Sciences: Nucleic acid biochemistry, B5. Ed. R.A. Flavell, Elsevier Scientific Publishers, Ireland, Ltd., 1983.
13. McKinnon, R.D. and Graham F.L. Transformation of mammalian cells with DNA using the calcium technique. Microinjection and Organelle transplantation techniques: Methods and Applications. J.E. Celis, A. Graessmann, and A. Loyter (Eds.) Academic Press (London) pp. 199-214, 1986.
14. Graham, F.L This week's citation classic Current contents/Life Sciences/Clinical Medicine. November 14, 1988.
http://garfield.library.upenn.edu/classics1988/A1988Q713700001.pdf
17. C.M. Counter, A.A. Avilion, C.E. LeFeuvre, N.G. Stewart, C.W. Greider, C.B. Harley and S. Bacchetti Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11,1921-1929, 1992
18. Graham, F.L. This week's citation classic. Current contents/Life Sciences February 24, 1992.
http://garfield.library.upenn.edu/classics1992/A1992HC31200001.pdf
19. Krougliak, V. and Graham, F. L. Development of cell lines capable of complementing E1, E4 and protein IX defective adenovirus type 5 mutants. Human Gene Therapy 6: 1575-1586, 1995
22. Shaw, G., Morse, S., Ararat, M. and Graham, F.L. Preferential transformation of human cells by human adenoviruses and the origins of HEK 293 cells. FASEB J., 16: 869-871, 2002
23 Graham, F.L. and Prevec, L. Manipulation of adenovirus vectors Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Techniques. Eds. E.J. Murray and J.M. Walker. Humana Press Inc., Clifton, N.J. pp 109-128, 1991
24. Bett, A. J., Prevec, L., and Graham, F. L Packaging capacity and stability of human adenovirus type 5 vectors J. Virol. 67: 5911- 5921, 1993
25. Bett, A. J., Haddara, W., Prevec, L. and Graham, F.L An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3 Proc. Natl. Acad. Sci. US 91: 8802-8806, 1994
26 Hitt, M., Bett, A.J., Prevec, L. and Graham, F.L Construction and propagation of human adenovirus vectors Cell Biology: A Laboratory Handbook Ed. J. E. Celis. Academic Press. pp. 479-490, 1994
27. Graham, F. L. and Prevec, L. Methods for construction of adenovirus vectors. Molecular Biotechnology 3: 207-220, 1995
28. Mittal, S. K., Prevec, L., Graham, F. L. and Babiuk, L. A. Development of a bovine adenovirus type 3 based expression vector J. Gen. Virol. 76: 93- 102, 1995
29. Hitt, M., Bett, A.J., Addison, C., Prevec, L. and Graham, F.L Techniques for human adenovirus vector construction and characterization Methods in Molecular Genetics" Ed. K. W. Adolph, Academic Press. Orlando, Florida. Vol. 7B, pp 13-30, 1995
30. Bramson, J., Graham, F. L. and Gauldie, J. The use of adenoviral vectors for gene therapy and gene transfer in vivo Curr. Opinion in Biotechnology. 6, 590-595, 1995
31. Hitt, M., Addison, C. and Graham, F.L Human adenovirus vectors for gene transfer into mammalian cells Advances in Pharmacology - Gene Therapy" Ed. J. Thomas August, Academic Press. San Diego, CA. 40: 137-206, 1997
32. Addison, C. L., Hitt, M., Kunsken, D. and Graham, F. L. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression in adenoviral vectors. J. Gen. Virol. 78: 1653-1661, 1997
33. Foley, R., Walker, I., Carter, R., Wan, Y. H., Boyle, M., Braciak, T., Addison, C., Graham, F. and Gauldie J. Intramarrow cytokine gene transfer by adenoviral vectors in dogs Human Gene Ther. 8:545-553, 1997
34. Thibault, V., Terlain, B., Graham, F. L. and Gauldie, J. Construction and characterization of a replication deficient adenovirus expressing rat soluble interleukin-6 receptor Molec. Med. 3: 519-529, 1997
35. Di Francesco, C., Cracco, C., Tomanin, R., Picci, L., Ventura, L., Zacchello, F., Di Natale, P., Anson, D. S., Hopwood, J. J., Graham, F.L. and Scarpa, M. In vitro correction of iduronate -2-sulfatase deficiency by adenovirus-mediated gene transfer Gene Therapy 4: 442-448, 1997
36. Hitt, M., Bett, A.J., Prevec, L. and Graham, F.L L Construction and propagation of human adenovirus vectors Cell Biology: A Laboratory Handbook Ed. J. E. Celis. Academic Press. 2nd Edition, Vol. 1, pp 500-512, 1998
37. Hitt, M.M., R.J. Parks, and F.L. Graham Structure and genetic organization of adenovirus vectors The Development of Human Gene Therapy, T. Friedman (ed.), Cold Spring Harbor Press, Cold Spring Harbor pp 61-86, 1998.
38 Stewart, A. K., Schimmer, A.D., Bailey, D. J., Dube, I. D., Cappe, D., Moen, R., Gauldie, J., and Graham, F. L In vivo adenoviral- mediated gene transfer of interleukin 2 in cutaneous plasmacytoma Blood 91: 1095-1097, 1998
39. Ng, P., Parks, R. J., Cummings, D. T., Evelegh, C. M., Sankar, U. and Graham, F. L. A high efficiency Cre/loxP based system for construction of adenoviral vectors Human Gene Therapy 10: 2667-2672, 1999
40 Graham, F. L. Adenovirus vectors for high efficiency gene transfer into mammalian cells Immunology Today. 21: 426-428, 2000
41 Hitt, M.M. and F.L. Graham Adenovirus vectors for human gene therapy Advances in Virus Research, Vol 55, 479-505. J. Glorioso (ed.), Academic Press, 2000
42 Ng, P., Parks, R. J., Cummings, D. T., Evelegh, C. M., Sankar, U. and Graham, F. L. An enhanced system for construction of adenoviral vectors by the two plasmid rescue method . Human Gene Therapy 11: 693-699, 2000
43 Ng, P. and Graham, F. L Construction of first generation adenoviral vectors Methods in Molecular Medicine. Gene Therapy Protocols, 2nd edition. Jeffrey R. Morgan (Ed). Humana Press Inc. Totawa, NJ. Vol. 69, pp. 389-414, 2002
44 Ha M.N., Graham F.L., D'Souza C.K., Muller W.J., Igdoura S.A., Schellhorn H.E. . Functional rescue of vitamin C synthesis deficiency in human cells using adenoviral-based expression of murine l-gulono-gamma-lactone oxidase Genomics. 83: 482-92, 2004
45 Maelandsmo G.M., Ross P.J., Pavliv M., Meulenbroek R.A., Evelegh C., Muruve D.A., Graham F.L., Parks R.J. Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice J Gene Med. 7: 307-15, 2005
46 Hitt, M., Ng, P. and Graham, F. L Construction and propagation of human adenovirus vectors Cell Biology: A Laboratory Handbook Ed. J. E. Celis. Academic Press. 3rd Edition, pp 435-443, 2005
47 Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A. and Graham, F. L. A new helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal Proc. Natl. Acad. Sci. U.S. 93: 13565-13570, 1996
48 Parks, R. J. and Graham, F. L A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging J. Virol. 71: 3293-3298, 1997
49 Schiedner, G., Morral, N., Parks, R. J., Wu, Y., Koopmans, S. C., Langston, C., Graham, F. L., Beaudet, A. L. and Kochanek, S. Genomic DNA transfer with a high capacity adenovirus vector results in improved in vivo expression and decreased toxicity Nature Genetics 18: 180-183, 1998
50 Morral, N., Parks, R. J., Zhou, H., Langston, C., Schiedner, G., Quinones, J., Graham, F. L., Kochanek, S. and Beaudet, A. L. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of "1-antitrypsin with negligible toxicity Human Gene Therapy, 10: 2709-2716, 1998
51 Morsy, M. A., Gu, M.C., Motzel, S., Zhao, J., Lin, J., Su, Q., Allan, H., Franlin, L., Parks, R. J., Graham, F. L., Kochanek, S., Bett, A. J. and Caskey, C. T. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of an leptin transgene. Proc. Natl. Acad. Sci US. 95:7866-7871, 1998
70 . Ebata, S. N., Prevec, L., Graham, F.L., and Dimock, K. Function and Immunogenicity of Human Parainfluenza Virus-3 Glycoproteins Expressed by Recombinant Adenoviruses . Virus Research 24: 21-33, 1992
52 Parks, R. J., Bramson, J. L., Wan, Y., Addison, C. L. and Graham, F. L. Effects of stuffer DNA on transgene expression from helper-dependent adenoviral vectors J. Virol. 73: 8027-8034, 1999
53 Parks, R. J., Evelegh, C. M. and Graham, F. L. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration Gene Therapy. 6: 1565-1573, 1999
54 Cregan, S. P., MacLaurin, J., Gendron, T. F., Callaghan, S. A., Park, D. S., Parks, R. J., Graham, F. L., Morley, P. and Slack, R. S. Helper dependent adenovirus vectors: their use as a gene delivery system to neurons Gene Therapy. 14:1200-1209, 2000
55 O’Neal, W.K., Zhou, H., Morral, N., Langstron, C., Parks, R. J., Graham, F. L., Kochanek, S., and Beaudet, A. L. Toxicity associated with repeated administration of first generation adenoviral vectors does not occur with a helper-dependent vector Mol. Med. 6:179-195, 2000
56 . Ng, P., Beauchamp, C., Evelegh, C. M., Parks, R. and Graham, F. L. Development of a FLP/frt system for generating helper-dependent adenoviral vectors Molec. Ther. 3: 809-815, 2001
57 Ng, P., Parks, R. J. and Graham, F. L. Preparation of helper dependent adenoviral vectors Methods in Molecular Medicine. Gene Therapy Protocols, 2nd edition.. Jeffrey R. Morgan (Ed). Humana Press Inc. Totawa, NJ. Vol. 69, pp. 371-388, 2002
58 Ng, P. and Graham, F. L. Helper dependent adenoviral vectors for gene therapy Gene Therapy: Therapeutic Mechanisms & Strategies, 2nd edition. Nancy S. Templeton (Ed). Marcel Dekker Inc. New York NY Ch 4, pp. 53-71, 2003
64 McDermott, M.R., Graham, F.L., Hanke, T. and Johnson, D.C Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology 169: 244-247, 1989
59 Brown, B. D., Shi, C. X., Powell, S., Graham, F. L. and Lillicrap, D. Helper-dependent Adenoviral Vectors Mediate Therapeutic Factor VIII Expression for Several Months with Minimal Accompanying Toxicity in a Canine Model of Severe Hemophilia A Blood. 103:804-10, 2004
60 Brown, B. D., Shi, C. X., Rawle, F. E.M.., Tinlin, S., McKinven, A., Graham, F. L. and Lillicrap, D. Factors Influencing Therapeutic Efficacy and the Host Immune Response to Helper-dependent Adenoviral Gene Therapy in Hemophilia A Mice J Thromb Haemost. 2: 111-8, 2004
61 Sargent, K. L., Ng, N., Evelegh, C., Graham, F. L. and Parks, R. J. Development of a size restricted pIX deleted helper virus for amplification of helper dependent adenovirus vectors Gene Ther. 11: 504-11, 2004
62 Shi C.X., Long M.A., Liu L., Graham F.L., Gauldie J., Hitt M.M. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells Mol Ther. 10: 758-67, 2004
63 Shi, C.X., Graham, F.L., and Hitt, M.M A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter J. Gene Med. 8: 442-451, 2006
65 Prevec, L., Schneider, M., Rosenthal, K.L., Belbeck, L.W., Derbyshire, J.B. and Graham, F.L. Use of human adenovirus based vectors for antigen expression in animals . J. Gen. Virol. 70: 429-434, 1989
66 Witmer, L.A., K,L. Rosenthal, F.L. Graham, H.M. Friedman, A. Yee and D.C. Johnson Cytotoxic T lymphocytes specific for herpes simplex virus (HSV) studied using adenovirus vectors expressing HSV glycoproteins J. Gen. Virol. 71: 387-396, 1990
67 Graham, F.L Adenoviruses as expression vectors and recombinant vaccines Trends in Biotechnology 8: 85-87, 1990
68 Prevec, L., Campbell, J.B., Christie, B.S., Belbeck, L. and Graham, F.L A recombinant human adenovirus vaccine against rabies J. Inf. Dis. 161: 27-30, 1990
69 Prevec, L. Christie, B.S., Laurie, K.E., Smith, M., Graham, F.L. and Rosenthal, K.L . Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and Rhesus macaque monkeys. J. Acquired Imm. Def. Syndr. 4: 568-576, 1991
71 Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccines Biotechnology. 1992;20:363-90
72 Both, G. W., Lockett, L. J., Janardhana, V., Edwards, S. J., Bellamy, A. R., Graham, F. L., Prevec, L., and Andrew, M. E. Protective immunity to rotavirus-induced diarrhoea is passively transferred to new-born mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc Virology 193, 940-950, 1993
73 Wesseling, J. G., Godeke, G.-J., Schijns, V. E. C. J., Prevec, L., Graham, F. L., Horzinek, M. C., and Rottier, P. J. M. Mouse Hepatitis Virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection J. Gen. Virol. 74: 2061-2069, 1993
74 Smerdou, C., Torres, J. M., Sanches, C. M., Sune, C., Anton, I. M., Medina, M., Castilla, J., Graham, F.L., and Enjuanes, L . Induction of an immune response to transmissible gastroenteritis coronavirus using vectors with enteric tropism Adv. Exp. Med. Biol. 342:455-62, 1993
75 . Gallichan, W. S., Johnson, D. C., Graham, F. L., Burke, R. L., and Rosenthal, K. L. Mucosal immunity and protection following intranasal immunization with recombinant adenovirus expressing Herpes Simplex Virus glycoprotein B J. Inf. Dis. 168:622-629, 1993
76 . Gallichan, W. S., Johnson, D. C., Graham, F. L. and Rosenthal, K. L. Mucosal immunization with a recombinant adenovirus vector induces local and systemic immunity and protection from herpes simplex virus Adv. Exp. Med. Biol. 371: 1581-1585, 1995
77 Torres, J. M., Sanches, C., Sune, C., Smerdou, C., Prevec, L., Graham, F. L., and Enjuanes, L. Induction of antibodies protecting against transmissible gastroenteritis coronavirus by recombinant adenovirus expressing TGEV spike protein Virology 213: 503-516, 1995
78 Yarosh, O. K., Wanderer, A. I., Graham, F. L., Campbell, J. B. and Prevec, L Human adenovirus type 5 vectors expressing rabies glycoprotein Vaccine. 14: 1257-1264, 1996
79 Torres, J. M., Alonso, C., Ortega, A., Mittal, S., Graham, F. L. and Enjuanes, L Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus J. Virol. 70: 3770-3780, 1996
80 Greenberger, M. J., Kunkel, S. L., Strieter, R. M., Lukacs, N. W., Bramson, J., Gauldie, J., Graham, F. L., Hitt, M., Danforth, J. M. and Standiford, T. J. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia J. Immunol. 157: 3006-3012, 1996.
81 . Matthews, D. A., Cummings, D., Evelegh, C., Graham, F. L. and Prevec, L. Development of a modified 293 cell line expressing the lac repressor and its use in the rescue of recombinant adenoviruses expressing high levels of rabies glycoprotein (G) J. Gen. Virol. 80: 345-53, 1999
82 Gabaglia, C. R., Pedersen, B., Hitt, M., Burdin, N., Sercarz, E. E., Graham, F. L., Gauldie, J. and Braciak, T.A. A single intramuscular injection with an adenovirus expressing interleukin-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4 expressing vector increases disease susceptibility in B10.D2 mice J. Immunol. 162:753-760, 1999
83 . Lubberts, E., Joosten, L.A., van Den Bersselaar, L., Helsen, M.M, Bakker, A.C,, van Meurs, J.B., Graham, F.L., Richards, C.D. and van Den Berg, W.B. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with c3llagen-induced arthritis prevents cartilage destruction J. Immunol 163:4546-4556, 1999
84 Braciak, T. A., Gallichan, W. S., Graham, F. L., Richards, C. D., Ramsay, A. J., Rosenthal, K. L. and Gauldie. J. Recombinant adenovirus vectors expressing interleukin 5 and 6 specifically enhance mucosal IgA responses in the lung Immunology 101:388-396, 2000
85 Gabaglia C.R., Sercarz E.E., Diaz-De-Durana Y., Hitt M., Graham F.L., Gauldie J., Braciak T.A. Life-long systemic protection in mice vaccinated with L. major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes Vaccine. 23:247-57, 2004
PMID: 15531044
86 See, R.H., Petric, M., Zakhartchouk, A.N., Lawrence, D.J., Mok, C. P.Y., Hogan, R. J., Rowe, T., Zitzow,L.A., Karunakaran ,K. P., Hitt, M.M., Graham, F. L., Prevec,L., Mahony, J. B., Sharon, C. Auperin, T., Rini, J.N. Tingle, A.J., Scheifele, D.W., Skowronski, D.M., Patrick, D.M., Babiuk, L.A., Gauldie, J., Voss, T.G., Roper, R.L., Brunham, R.C. and Finlay, B.B.. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS-Coronavirus J. Gen. Virol. 87: 641-650, 2006
87 Wang, J., Thorson, L., Stokes, R.W., Santosuosso, M., Huygen, K., Zganiacz, A., Hitt, M., and Xing, Z. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis J. Immunol. 173: 6357-65, 2004
88 Santosuosso, M., Zhang, X., McCormick, S., Wang, J., Hitt, M., and Xing, Z Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen J. Immunol. 174: 7986-94, 2005
89 Addison, C. A., Braciak, T., Ralston, R., Muller, W. J., Gauldie, J. and Graham, F. L. Intratumoural injection of an adenovirus expressing interleukin-2 induces tumour regression and long term immunity in a murine breast cancer model Proc. Natl. Acad. Sci. US. 92: 8522-8526, 1995
90 Addison, C. A., Gauldie, J., Muller, W. J. and Graham, F. L. An adenovirus vector expressing interleukin-4 modulates tumorigenicity and induces regression in a murine breast cancer model Int. J. Oncology, 7: 1253-1260, 1995
91 Bramson, J.L., Hitt, M., Gallichan, W.S., Rosenthal, K.L., Gauldie, J., and Graham, F.L. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12 Human Gene Therapy 7, 333-342, 1996
92 Bramson, J., Hitt, M., Addison, C.L., Muller, W. J., Gauldie, J. and Graham, F. L. Direct intratumoral injection of an adenovirus expressing IL-12 induces regression and long-lasting immunity which is associated with highly localized expression of IL-12 Human Gene Therapy 7: 1995-2002, 1996
93 Bramson, J.L., Hitt, M., Gauldie, J., and Graham, F.L Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination Gene Therapy4, 1069-1076, 1997
94 Putzer, B. M., Hitt, M., Muller, W. J., Emtage, P., Gauldie, J. and Graham, F. L. Interleukin-12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression Proc. Natl. Acad. Sci. US 94: 10889-10894, 1997
98 Addison, C. L., Bramson, J. L., Hitt, M., Muller, W. J., Gauldie, J. and Graham, F. L. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors Gene Therapy 5:1400-1409, 1998
95 Stewart. A. K., Lassam, N., Graham, F. L., Gauldie, J., Addison, C. L., Bailey, D. J., Dessureault, S., Dube, I. D., Gallenger, S., Krajden, M., Rotstein, L. E., Quirt, I. C. and Moen, R. Clinical Protocol: A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma. . Human Gene Ther. 8: 1403-1414, 1997
96 Marr, R. A., Addison, C. A., Snider, D., Muller, W. J., Gauldie, J. and Graham, F. L. Tumour immunotherapy using an adenoviral vector expressing a membrane bound mutant of murine TNF alpha. Gene Therapy 4: 1181-1188, 1997
97 Putzer, B. M., Bramson, J. L., Addison, C. L., Hitt, M., Siegel, P. M., Muller, W. J. and Graham, F. L Combination therapy with IL-2 and wild-type p53 expressed by Ad-vectors potentiates tumor regression in a murine model of breast cancer Human Gene Therapy. 9: 707-718, 1998
99 Marr, R.A., Hitt, M., Muller, W.J., Gauldie, J., and Graham, F.L. Tumour therapy in mice using adenovirus vectors expressing human TNF alpha Int. J. Oncol.12, 509-515, 1998
105 Gyorffy, S., Palmer, K., Podor, T., Hitt, M., and Gauldie, J. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and interleukin 12: A role for combined anti-angiogenesis and immunotherapy J. Immunol. 166:6212-7, 2001
104 Wen XY, Mandelbaum S, Li ZH, Hitt M, Graham FL, Hawley TS, Hawley RG, Stewart AK. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma Cancer Gene Ther 5:361-370, 2001
102 Putzer , B. M, Stiewe, T., Rodicker, F., Schildgen, O., Ruhm, S., Dirsch, O., Fiedler, M., Dahmen, U., Tennant, B, Scherer, C., Graham, F.L. and Roggendorf, M. Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes J Natl Cancer Inst. 93:472-479, 2001
101 Stewart. A. K., Lassam, N., Quirt, I. C., Bailey, D. J., Rotstein, L. E., Krajden, M., Dessureault, S., Gallenger, S., Cappe, D., Wan, Y. H., Addison, C. A., Moen, R., Gauldie, J. and Graham, F. L Adenovector-mediated gene delivery of interleukin 2 in metastatic breast cancer and melanoma: results of a phase I clinical trial. Gene Therapy. 6: 350-363, 1999
103 Trudel, S., Li, Z., Dodgson, C., Nanji, S., Wan, Y., Voralia, M., Hitt, M., Graham, F. L., Gauldie, J. and Stewart. A. K. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase I study . Leukemia 15: 846-854, 2001
100 Marr, R.A., Hitt, M.M., Gauldie, J., Muller, W.J., and Graham, F.L A p75 TNF receptor specific mutant of murine TNF alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity Cancer Gene Therapy6, 465-474, 1999
106 Palmer, K., Hitt, M., Emtage, P., Gyorffy, S., and Gauldie, J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor activity Gene Therapy8: 282-90, 2001
107 Chen, Y., Emtage, P., Zhu, Q., Foley, R., Muller, W., Hitt, M.M., Gauldie, J., and Wan, Y.-H Induction of ErbB-2/neu specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: Enhanced efficiency by co-transduction of gene encoding IL-12. Gene Therapy 8:316-23, 2001
110 Gabaglia, C.R., DeLaney, A., Gee, J., Halder, R., Graham, F.L., Gauldie, J., Sercarz, E.E. and Braciak, T.A. Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the tumor sentinel lymph nodes of mice J. Transl. Med., 8:98, 2010
108 Trudel, S., Trachtenberg, J., Dancey, J., Toi, H., Sweet, J., Jewitt, M., Li, Z., Zhuang, L., Wan, Y., Hitt, M., Graham, F. L., Gauldie, J. and Stewart. A. K. A phase I trial of adenovector mediated delivery of interleukin-2 (AdIL-2) in locally advanced prostate cance Cancer Gene Therapy, 10:755-63. 2003
109 Gabaglia, R. C., de Durana, D. Y., Graham, F.L., Gauldie, J., Sercarz, E.E. and Braciak, T.A. Attenuation of the Glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors Cancer Research 67: 2290-2297, 2007
111 Sadeghi, H. and Hitt, M.M. Transcriptionally targeted adenovirus vectors Transcriptionally targeted adenovirus vectors Current GeneTherapy 5: 411-427, 2005
112 MacLeod, S.H., Elgadi, M. M., ,Bossi, G., Sankar, U., Pisio, A., Agopsowicz, K., Sharon, D., Graham, F.L., and Hitt, M.M. HER3-targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice. Cancer Gene Therapy 19: 888-98, 2012
Calcium Phosphate DNA Transfection
HEK 293 Cells
First Generation Ad Vectors
Helper Dependent Ad Vectors
Ad Vectors as Vaccines
Ad Vectors in Cancer Therapy
Patents
Title: Adenovirus vectors for gene therapy.
Date Issued: October 31, 2000 US Patent No. 6,140,087
Inventors: Graham, F. L., Bett, A., Haddara, W., Prevec, L.
Title: Recombinant protein production in bovine adenovirus expression vector system.
Date Issued: Oct. 13, 1998 US Patent No. 5,820,868
Inventors: Mittal, S., Graham, F. L., Prevec, L.,, and Babiuk, L.
Title: Bovine adenovirus expression vector system
Date Issued: July 11, 2000 US Patent No. 6,086,890
Inventors: Mittal, S., Graham, F. L., Prevec, L., and Babiuk, L.
Title: Mammalian cell lines expressing bovine adenovirus functions
Date Issued: April 30, 2002 US Patent No. 6,379,944
Inventors: Mittal, S., Graham, F. L., Prevec, L., Babiuk, L. and Tikoo; S.K.
Title: Rabies recombinant adenovirus
Date Issued: August 26, 1998 EP859846A1
Inventors: Yarosh, O. K., Prevec, L. and Graham, F. L.
Title: Adenovirus vectors for gene therapy
Date Issued: July 6, 1999 US Patent No. 5,919,676
Inventors: Graham, F. L., Anton, M, Rudnicki, M.
Title: Adenovirus vectors for gene therapy
Date Issued: May 4, 2004 US Patent No. 6,730,507
Inventors: Graham, F. L., Anton, M, Rudnicki, M.
Title: Adenovirus vectors for gene Therapy
Date Issued: January 11, 2001 AU724161
Inventors: Graham, F. L., Anton, M, Rudnicki, M.
Title: Improved adenoviruses generated from helper viruses and helper dependent vectors
Date Issued: June 27, 2000 US Patent No. 6,080,569
Inventors: Graham, F. L., Chen, L. and Parks, R.
Title: Adenoviruses for control of gene expression
Date Issued: September 19, 2000 US Patent No. 6,120,764
Inventors: Graham, F. L., Anton, M, Bacchetti, S., Wang, P., Rudnicki, M., Muller., W.
Title: Adenoviruses for control of gene expression
Date Issued: December 13, 2005 US Patent No. 6,974,694
Inventors: Graham, F. L., Anton, M, Bacchetti, S., Wang, P., Rudnicki, M., Muller., W.
Title: A high efficiency Cre/LoxP based system for construction of adenovirus vectors.
Date Issued: April 30, 2002 US Patent No. 6,379,943
Inventors: Graham, F. L., Parks, R. and Ng, P.
Title: Enhanced system for construction of adenovirus vectors.
Date Issued: February 15, 2005 US Patent No. 6,855,534B2
Inventors: Graham, F. L., Parks, R. and Ng, P.
Title: Enhanced system for construction of adenovirus vectors.
Date Issued: June 29, 2004 US Patent No. 6,756,226B2
Inventors: Graham, F. L., Parks, R. and Ng, P.
Title: A system for production of helper dependent adenovirus vectors based on use of endonucleases
Date Issued: November 14, 2006 US Patent No. 7,135,187
Inventors: Graham, F. L., Parks, R., Ng, P.
Title: Production of Adenovirus Vectors with Reduced Levels of Replication Competent Adenovirus Contamination
Date Issued: March 13, 2007 US Patent No. 7,189,561
Inventors: F. L. Graham
Title: Recombinant bovine adenoviruses
Date Issued December 14, 1999 US Patent No. 6,001,591
Inventors: Mittal, S., Graham, F. L., Prevec, L.,, and Babiuk, L.